knowledge -WSS

knowledge

author：explore 2025-09-06 04:15:09 - browse：39

The Food and Drug Administration is poised to tell drug and medical device makers how to better include people of color in the clinical trials that test whether products work and are safe, an agency official said Wednesday. Those guidelines are five months late.

To ensure that drugs work for everyone, they must be tested on a representative sample of people. But researchers have found that many clinical trials exclude the people of color who are often most affected by the diseases that drugs treat.

To help fix that problem, Congress passed a law requiring companies to give the FDA their plans for diversifying clinical trials. As part of that process, the agency was expected to issue guidance by the end of last year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

Wikipedia

explore

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

How AI can help patients find reliable information about doctors

J&J lung cancer data amount to new salvo against AstraZeneca

STAT Summit: Meghan O’Rourke on making chronic illness visible

FDA weighs limits of animal data in assessing artificial wombs

How the messy conversation about Dolly changed bioethics

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Medicare details structure of new drug price negotiation program

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

Continuity nursing helped my family in our darkest PICU moments

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Cancer drug shortages should be causing more outrage

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Jerome Adams on the need for new antivirals for Covid

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Cancer drug shortages should be causing more outrage

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

knowledge

Study on Amgen’s bispecific immunotherapy produces positive data

Fed up with FDA, ALS advocates consider a take

Roche acquires Telavant from Roivant, adding experimental IBD treatment

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

Wikipedia

explore

leisure time